Thrivent Financial for Lutherans Buys 1,262,193 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Thrivent Financial for Lutherans raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 140.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,159,356 shares of the biopharmaceutical company’s stock after acquiring an additional 1,262,193 shares during the quarter. Thrivent Financial for Lutherans owned about 0.17% of Gilead Sciences worth $148,153,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GILD. Gilbert & Cook Inc. grew its position in shares of Gilead Sciences by 5.3% during the 4th quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock worth $550,000 after purchasing an additional 344 shares in the last quarter. Aveo Capital Partners LLC grew its position in shares of Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock worth $443,000 after purchasing an additional 435 shares in the last quarter. TrinityPoint Wealth LLC grew its position in shares of Gilead Sciences by 2.9% during the 4th quarter. TrinityPoint Wealth LLC now owns 5,708 shares of the biopharmaceutical company’s stock worth $462,000 after purchasing an additional 159 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 6.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 3,295 shares of the biopharmaceutical company’s stock worth $267,000 after acquiring an additional 211 shares in the last quarter. Finally, Allstate Corp boosted its position in shares of Gilead Sciences by 4.7% during the 4th quarter. Allstate Corp now owns 4,062 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 183 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,847 shares of company stock valued at $3,002,940. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on GILD shares. Truist Financial increased their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research note on Wednesday, September 4th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a research note on Monday, July 8th. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $82.06.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $83.94 on Friday. The business’s 50-day moving average price is $76.95 and its two-hundred day moving average price is $71.26. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The stock has a market cap of $104.58 billion, a P/E ratio of 233.17, a PEG ratio of 2.80 and a beta of 0.18. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.